BMY Bristol-Myers Squibb Company
Company Analysis
Latest News
Bristol Myers faces $6.7B lawsuit, over alleged Celgene drug approval delays
The 2nd U.S. Circuit Court of Appeals reinstated a $6.7 billion lawsuit against Bristol Myers Squibb. Former Celgene shareholders allege the company...
Bristol-Myers Squibb Receives Bullish Q4 Earnings Forecast from Zacks Research
Zacks Research raised its fourth-quarter 2026 earnings per share (EPS) estimate for Bristol-Myers Squibb to $1.64, up from $1.50. The firm also increased its...
Bristol Myers Squibb builds $2.3 billion Houston campus, speeding drug delivery
Bristol Myers Squibb (BMY) is investing $2.3 billion to construct a new manufacturing campus in Houston, Texas. The campus will span 600,000 square feet. The...
🟢 Bristol-Myers Squibb is trading 7.6% up today after strong Q2 earnings and a guidance hike
Bristol-Myers Squibb is trading at $70.24 (7.6% up) today following a strong Q2 2026 earnings report and a substantial full-year guidance raise. • Management...
AstraZeneca Weighs Bristol Myers Merger, Targeting $400 Billion Market Value
UK-based AstraZeneca Plc held preliminary merger talks with U.S. rival Bristol Myers Squibb Co. The Financial Times reported the discussions citing people...
Bristol Myers Squibb's second quarter revenue of $13.0B and EPS of $2.04 beat estimates, prompting a raised full-year 2026 outlook.
Bristol Myers Squibb reported second quarter 2026 revenues of $13.0 billion, up 6% year-over-year, and a non-GAAP EPS of $2.04. The results significantly...
Bristol-Myers Squibb Company Q2 2026 Earnings Preview: What Analysts Expect on July 30, 2026
Bristol-Myers Squibb is expected to report Q2 2026 revenue of $11.67 billion and an adjusted EPS of $1.59, with the current stock price of $62.54 trading just...
🔴 Bristol-Myers Squibb is trading 4.2% down today on broad healthcare sector pullback
Bristol-Myers Squibb is trading 4.2% down at $56.88 following a broad pullback in healthcare names. • Shares are on pace for their largest percentage decline...
Bristol Myers Squibb Myeloma Drug Enters FDA Review, Cuts Progression Risk 52%
The U.S. Food and Drug Administration (FDA) accepted Bristol Myers Squibb’s New Drug Application for mezigdomide. This oral treatment targets patients with...
Bristol Myers Squibb’s Krazati Misses Trial Goals, Threatening FDA Approval
Bristol Myers Squibb announced that its cancer drug Krazati failed to meet primary efficacy endpoints in the Phase 3 KRYSTAL-10 confirmatory trial. The study...
Bristol Myers Squibb Faces House Probe, Citing China Military Hospital Links
The U.S. House Select Committee on China launched an investigation into Bristol Myers Squibb, Merck, Pfizer, and AbbVie regarding clinical trials in China....
🟢 BMY is trading 4% up today with no clear company-specific catalyst
BMY is trading 4% up at $57.63 despite a lack of fresh company-specific headlines or catalysts. • The move appears stock-specific as broader market indices...
Bristol Myers Squibb Cuts Myeloma Risk by 52% With Mezigdomide
Bristol Myers Squibb announced positive results for two multiple myeloma treatments at the European Hematology Association (EHA) 2026 Congress. The Phase III...
Takeda beats Bristol Myers in psoriasis trial, showing 2.5x better clearance
Takeda’s experimental oral drug zasocitinib outperformed Bristol Myers Squibb’s approved therapy, Sotyktu, in a late-stage head-to-head trial. Over 35% of...
Bristol Myers Squibb Cancer Drug Beats Chemotherapy, Hitting Phase 3 Goals
Bristol Myers Squibb and partner SystImmune announced positive results from two Phase 3 trials for the investigational cancer drug izalontamab brengitecan...
🔴 Bristol-Myers Squibb Company is trading 4.3% down today as investors lock in gains following EU Opdivo combo approval
Bristol-Myers Squibb Company is trading 4.3% down at $54.70 today as investors lock in gains following a rally driven by positive regulatory news. • The stock...
Bristol Myers Squibb Wins EU Approval for Opdivo, First Lymphoma Immunotherapy Combo
The European Commission approved Bristol Myers Squibb’s Opdivo in combination with AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine). This regimen...
Bristol Myers Squibb cuts myeloma progression risk 52% with mezigdomide
Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 trial results for its multiple myeloma drug, mezigdomide. The company presented these findings at the 2026...
Bristol-Myers Squibb maintains Buy rating, citing milvexian trial potential
UBS reaffirmed its Buy rating for Bristol-Myers Squibb. The investment bank set a price target of $70.00 for the stock. Analysts identify milvexian, a Factor...
Bristol Myers Squibb Partners with Anthropic to Deploy Claude AI Across Global Operations
Bristol Myers Squibb has partnered with Anthropic to deploy Claude as an enterprise-wide AI platform, aiming to accelerate drug discovery and operational...